Merck Comes Prepared This Time As Sugammadex Faces Second Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
After failing to submit safety data on time during the drug’s first FDA review, Merck has its data together and is armed with a new hypersensitivity study in advance of the second panel review for its anesthesia product.
You may also be interested in...
Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.
Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.
Merck On Track To File Novel Sleep Aid Suvorexant In 2012
Merck announced its potential first-in-class dual orexin receptor antagonist suvorexant successfully completed a second Phase III trial, apparently without safety concerns that led Actelion/GlaxoSmithKline to drop their DORA almorexant a year ago on Phase III results.